Last reviewed · How we verify
Bispecific antibody
Binds to CD16A and CD19 to activate antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis
Binds to CD16A and CD19 to activate antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis Used for Treatment of relapsed or refractory diffuse large B-cell lymphoma.
At a glance
| Generic name | Bispecific antibody |
|---|---|
| Sponsor | Sung-Soo Park |
| Drug class | Bispecific antibody |
| Target | CD16A and CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bispecific antibodies are designed to bind to two different antigens, in this case CD16A and CD19, to enhance the immune response against cancer cells.
Approved indications
- Treatment of relapsed or refractory diffuse large B-cell lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma (PHASE1, PHASE2)
- A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (PHASE2)
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (PHASE1)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |